Nigel Suren Kanagasundaram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nigel Suren Kanagasundaram has a total of 313 co-authors. Here are the top co-authors by number of shared publications:
Emil P. Paganini
6 shared publicationsA. Brett Larive
3 shared publicationsAndrew Heed
Department of Pharmacy , Newcastle upon Tyne Hospitals NHS Foundation Trust , Newcastle upon Tyne , UK
3 shared publicationsJ H Turney
General Infirmary at Leeds Leeds and 2Scarborough Hospital Scarborough UK
3 shared publicationsA. M. Davison
2 shared publicationsAndrew Lewington
2 shared publications
Latest Publications
- Open Access
- 19 February 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-9
Mitochondrial Haplogroup and the Risk of Acute Kidney Injury Following Cardiac Bypass Surgery
Although mitochondrial dysfunction plays a key role in the pathophysiology of acute kidney injury (AKI), the influence of mitochondrial genetic variability in this process remains unclear. We explored the association between the risk of post-cardiac bypass AKI and mitochondrial haplotype – inherited mitochondrial genomic variations of potentially functional significance. Our single-centre study recruited consecutive patients prior to surgery. Exclusions included stage 5 CKD, non-Caucasian race and subsequent off-pump surgery. Haplogroup analysis allowed characterisation of the study population using the common mutations and by phylogenetic supergroup (WXI and HV). Chi-square tests for association allowed the identification of potential predictors of AKI for use in logistic regression analysis. AKI occurred in 12.8% of the study population (n = 881; male 69.6%, non-diabetic 78.5%, median (interquartile range) age 68.0 (61.0–75.0) years). The haplogroup profile comprised H (42.7%), J (12.1%), T (10.9%), U (14.4%) and K (7.6%). Although the regression model was statistically significant (χ2 = 95.483, p < 0.0005), neither the phylogenetic supergroups nor any individual haplogroup was a significant contributor. We found no significant association between common European haplogroups and the risk of post-cardiac bypass AKI. However, given the major role of mitochondrial dysfunction in AKI, there is a need to replicate our findings in other cohorts and with other aetiologies of AKI.
- 19 February 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-9
Open AccessMitochondrial Haplogroup and the Risk of Acute Kidney Injury Following Cardiac Bypass Surgery
Although mitochondrial dysfunction plays a key role in the pathophysiology of acute kidney injury (AKI), the influence of mitochondrial genetic variability in this process remains unclear. We explored the association between the risk of post-cardiac bypass AKI and mitochondrial haplotype – inherited mitochondrial genomic variations of potentially functional significance. Our single-centre study recruited consecutive patients prior to surgery. Exclusions included stage 5 CKD, non-Caucasian race and subsequent off-pump surgery. Haplogroup analysis allowed characterisation of the study population using the common mutations and by phylogenetic supergroup (WXI and HV). Chi-square tests for association allowed the identification of potential predictors of AKI for use in logistic regression analysis. AKI occurred in 12.8% of the study population (n = 881; male 69.6%, non-diabetic 78.5%, median (interquartile range) age 68.0 (61.0–75.0) years). The haplogroup profile comprised H (42.7%), J (12.1%), T (10.9%), U (14.4%) and K (7.6%). Although the regression model was statistically significant (χ2 = 95.483, p < 0.0005), neither the phylogenetic supergroups nor any individual haplogroup was a significant contributor. We found no significant association between common European haplogroups and the risk of post-cardiac bypass AKI. However, given the major role of mitochondrial dysfunction in AKI, there is a need to replicate our findings in other cohorts and with other aetiologies of AKI.
- 28 November 2018
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 112 (3) , 197-205
Risk prediction for acute kidney injury in acute medical admissions in the UK
Acute Kidney Injury (AKI) is associated with adverse outcomes; therefore identifying patients who are at risk of developing AKI in hospital may lead to targeted prevention. We undertook a UK-wide study in acute medical units (AMUs) to define those who develop hospital-acquired AKI (hAKI); to determine risk factors associated with hAKI and to assess the feasibility of developing a risk prediction score. Prospective multi-centre cohort study across 72 AMUs in the UK. Data collected from all patients who presented over a 24-h period. Chronic dialysis, community-acquired AKI (cAKI) and those with fewer than two creatinine measurements were excluded. Primary outcome was the development of h-AKI. Two thousand four hundred and fourty-six individuals were admitted to the seventy-two participating centres. Three hundred and eighty-four patients (16%) sustained AKI of whom two hundred and eighty-seven (75%) were cAKI and ninety-seven (25%) were hAKI. After exclusions, chronic kidney disease [Odds Ratio (OR) 3.08, 95% Confidence Interval (CI) 1.96–4.83], diuretic prescription (OR 2.33, 95% CI 1.5–3.65), a lower haemoglobin concentration and elevated serum bilirubin were independently associated with development of hAKI. Multi-variable model discrimination was only moderate (c-statistic 0.75). AKI in AMUs is common and associated with worse outcomes, with the majority of cases community acquired. Only a small proportion of patients develop hAKI. Prognostic risk factor modelling demonstrated only moderate discrimination implying that widespread adoption of such an AKI clinical risk score across all AMU admissions is not currently justified. More targeted risk assessment or automated methods of calculating individual risk may be more appropriate alternatives.
- 28 November 2018
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 112 (3) , 197-205
Risk prediction for acute kidney injury in acute medical admissions in the UK
Acute Kidney Injury (AKI) is associated with adverse outcomes; therefore identifying patients who are at risk of developing AKI in hospital may lead to targeted prevention. We undertook a UK-wide study in acute medical units (AMUs) to define those who develop hospital-acquired AKI (hAKI); to determine risk factors associated with hAKI and to assess the feasibility of developing a risk prediction score. Prospective multi-centre cohort study across 72 AMUs in the UK. Data collected from all patients who presented over a 24-h period. Chronic dialysis, community-acquired AKI (cAKI) and those with fewer than two creatinine measurements were excluded. Primary outcome was the development of h-AKI. Two thousand four hundred and fourty-six individuals were admitted to the seventy-two participating centres. Three hundred and eighty-four patients (16%) sustained AKI of whom two hundred and eighty-seven (75%) were cAKI and ninety-seven (25%) were hAKI. After exclusions, chronic kidney disease [Odds Ratio (OR) 3.08, 95% Confidence Interval (CI) 1.96–4.83], diuretic prescription (OR 2.33, 95% CI 1.5–3.65), a lower haemoglobin concentration and elevated serum bilirubin were independently associated with development of hAKI. Multi-variable model discrimination was only moderate (c-statistic 0.75). AKI in AMUs is common and associated with worse outcomes, with the majority of cases community acquired. Only a small proportion of patients develop hAKI. Prognostic risk factor modelling demonstrated only moderate discrimination implying that widespread adoption of such an AKI clinical risk score across all AMU admissions is not currently justified. More targeted risk assessment or automated methods of calculating individual risk may be more appropriate alternatives.
- 1 April 2017
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 195 (7) , 955-958
The Use of Plasmapheresis in Patients with Bronchiectasis with Pseudomonas aeruginosa Infection and Inhibitory Antibodies
- 1 April 2017
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 195 (7) , 955-958
The Use of Plasmapheresis in Patients with Bronchiectasis with Pseudomonas aeruginosa Infection and Inhibitory Antibodies
- 10 October 2016
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 70 (10) , A32
Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies
Rationale: There are few salvage therapies for advanced bronchiectasis. Recently, we identified a subset of patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa infection (1). These patients had an excess of IgG2 specific to the bacterial O-antigen. This IgG2 inhibited immune killing of the infecting strain. Patients with inhibitory antibody had worse lung disease (1). Here we describe the treatment of two critically ill patients with non-cystic fibrosis bronchiectasis. Each patient had inhibitory antibodies, chronic Pseudomonas infection and had experienced clinical decline despite optimal conventional therapy. Objectives: To determine if removing inhibitory antibody from two critically ill patients would result in improved health. Methods: Inhibitory antibodies were removed by plasmapheresis (Pex). Blocking antibody levels were assessed longitudinally as (1). Measurements and Main Results: Post-plasmapheresis both patients had a significant and sustained drop in intravenous antibiotic use, days in hospital and CRP levels. Both patients also became Pseudomonas negative immediately after treatment. Over time the levels of anti-O-antigen IgG2 rose in both patients such that it reached titres equivalent to those measured before plasmapheresis. The return of high IgG2 titres correlated with the appearance of Pseudomonas in the sputum and worsening disease. Conclusion: Plasmapheresis of these two patients led to an immediate improvement in health and reduced clinical intervention. To our knowledge this is the first time plasmapheresis has been successfully used to treat respiratory infections. More cross sectional studies to define the rates of “blocking antibodies” are needed. Longitudinal studies are also needed to understand if these can be suppressed, at an earlier stage, by other less invasive means than plasmapheresis.
- 10 October 2016
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 70 (10) , A32
Plasmapheresis as rescue therapy in severe bronchiectasis with blocking anti pseudomonas antibodies
Rationale: There are few salvage therapies for advanced bronchiectasis. Recently, we identified a subset of patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa infection (1). These patients had an excess of IgG2 specific to the bacterial O-antigen. This IgG2 inhibited immune killing of the infecting strain. Patients with inhibitory antibody had worse lung disease (1). Here we describe the treatment of two critically ill patients with non-cystic fibrosis bronchiectasis. Each patient had inhibitory antibodies, chronic Pseudomonas infection and had experienced clinical decline despite optimal conventional therapy. Objectives: To determine if removing inhibitory antibody from two critically ill patients would result in improved health. Methods: Inhibitory antibodies were removed by plasmapheresis (Pex). Blocking antibody levels were assessed longitudinally as (1). Measurements and Main Results: Post-plasmapheresis both patients had a significant and sustained drop in intravenous antibiotic use, days in hospital and CRP levels. Both patients also became Pseudomonas negative immediately after treatment. Over time the levels of anti-O-antigen IgG2 rose in both patients such that it reached titres equivalent to those measured before plasmapheresis. The return of high IgG2 titres correlated with the appearance of Pseudomonas in the sputum and worsening disease. Conclusion: Plasmapheresis of these two patients led to an immediate improvement in health and reduced clinical intervention. To our knowledge this is the first time plasmapheresis has been successfully used to treat respiratory infections. More cross sectional studies to define the rates of “blocking antibodies” are needed. Longitudinal studies are also needed to understand if these can be suppressed, at an earlier stage, by other less invasive means than plasmapheresis.
- Open Access
- 18 December 2015
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 9 (1) , 57-62
Computerized clinical decision support for the early recognition and management of acute kidney injury: a qualitative evaluation of end-user experience
Although the efficacy of computerized clinical decision support (CCDS) for acute kidney injury (AKI) remains unclear, the wider literature includes examples of limited acceptability and equivocal benefit. Our single-centre study aimed to identify factors promoting or inhibiting use of in-patient AKI CCDS. Targeting medical users, CCDS triggered with a serum creatinine rise of ≥25 μmol/L/day and linked to guidance and test ordering. User experience was evaluated through retrospective interviews, conducted and analysed according to Normalization Process Theory. Initial pilot ward experience allowed tool refinement. Assessments continued following CCDS activation across all adult, non-critical care wards. Thematic saturation was achieved with 24 interviews. The alert was accepted as a potentially useful prompt to early clinical re-assessment by many trainees. Senior staff were more sceptical, tending to view it as a hindrance. ‘Pop-ups’ and mandated engagement before alert dismissal were universally unpopular due to workflow disruption. Users were driven to close out of the alert as soon as possible to review historical creatinines and to continue with the intended workflow. Our study revealed themes similar to those previously described in non-AKI settings. Systems intruding on workflow, particularly involving complex interactions, may be unsustainable even if there has been a positive impact on care. The optimal balance between intrusion and clinical benefit of AKI CCDS requires further evaluation.
- 18 December 2015
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 9 (1) , 57-62
Open AccessComputerized clinical decision support for the early recognition and management of acute kidney injury: a qualitative evaluation of end-user experience
Although the efficacy of computerized clinical decision support (CCDS) for acute kidney injury (AKI) remains unclear, the wider literature includes examples of limited acceptability and equivocal benefit. Our single-centre study aimed to identify factors promoting or inhibiting use of in-patient AKI CCDS. Targeting medical users, CCDS triggered with a serum creatinine rise of ≥25 μmol/L/day and linked to guidance and test ordering. User experience was evaluated through retrospective interviews, conducted and analysed according to Normalization Process Theory. Initial pilot ward experience allowed tool refinement. Assessments continued following CCDS activation across all adult, non-critical care wards. Thematic saturation was achieved with 24 interviews. The alert was accepted as a potentially useful prompt to early clinical re-assessment by many trainees. Senior staff were more sceptical, tending to view it as a hindrance. ‘Pop-ups’ and mandated engagement before alert dismissal were universally unpopular due to workflow disruption. Users were driven to close out of the alert as soon as possible to review historical creatinines and to continue with the intended workflow. Our study revealed themes similar to those previously described in non-AKI settings. Systems intruding on workflow, particularly involving complex interactions, may be unsustainable even if there has been a positive impact on care. The optimal balance between intrusion and clinical benefit of AKI CCDS requires further evaluation.
- 1 October 2015
- Published by Elsevier in Surgery (Oxford)
- Vol. 33 (10) , 491-497
Acute kidney injury in surgical patients
- 1 October 2015
- Published by Elsevier in Surgery (Oxford)
- Vol. 33 (10) , 491-497
Acute kidney injury in surgical patients
- Open Access
- 21 May 2015
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (suppl_3) , iii443
SP198ELECTRONIC CLINICAL DECISION SUPPORT FOR THE EARLY RECOGNITION AND MANAGEMENT OF ACUTE KIDNEY INJURY: QUALITATIVE EVALUATION OF END-USER EXPERIENCE
Introduction and Aims: Electronic clinical decision support (eCDS) systems have been suggested as a possible solution to deficiencies in AKI care and have been widely adopted despite limited evidence. The broader literature, however, describes alert fatigue, end-user disengagement and unintended consequences, particularly when systems are introduced with limited end-user input. A nationwide mandate now standardises the biochemical algorithm for reporting AKI but end-user interfaces remain heterogeneous with variations in IT capability, alert intrusiveness and accompanying content. Even a single, uniform eCDS may not suit all circumstances depending on the target user and local workflow. We undertook a single-centre, qualitative evaluation of end-user experience of an AKI eCDS to identify those factors affecting its use and incorporation into routine practice.
- 21 May 2015
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (suppl_3) , iii443
Open AccessSP198ELECTRONIC CLINICAL DECISION SUPPORT FOR THE EARLY RECOGNITION AND MANAGEMENT OF ACUTE KIDNEY INJURY: QUALITATIVE EVALUATION OF END-USER EXPERIENCE
Introduction and Aims: Electronic clinical decision support (eCDS) systems have been suggested as a possible solution to deficiencies in AKI care and have been widely adopted despite limited evidence. The broader literature, however, describes alert fatigue, end-user disengagement and unintended consequences, particularly when systems are introduced with limited end-user input. A nationwide mandate now standardises the biochemical algorithm for reporting AKI but end-user interfaces remain heterogeneous with variations in IT capability, alert intrusiveness and accompanying content. Even a single, uniform eCDS may not suit all circumstances depending on the target user and local workflow. We undertook a single-centre, qualitative evaluation of end-user experience of an AKI eCDS to identify those factors affecting its use and incorporation into routine practice.
- Open Access
- 21 May 2015
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (suppl_3) , iii453
SP228ELECTRONIC CLINICAL DECISION SUPPORT FOR THE EARLY RECOGNITION AND MANAGEMENT OF ACUTE KIDNEY INJURY: QUANTITATIVE EVALUATION OF OUTCOMES
Introduction and Aims: Electronic clinical decision support (eCDS) systems have been promoted to help address deficiencies in AKI care and have been widely adopted despite limited published evidence. However, eCDS implementation in other settings has been hampered by alert fatigue, end-user disengagement and unintended clinical consequences. These impediments to integration may hinder progress against the clinical outcomes which these tools were intended to target. With clinical efficacy, therefore, still uncertain, we undertook a single-centre, quantitative evaluation of outcomes after implementation of an AKI eCDS system within our organisation.
- 21 May 2015
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (suppl_3) , iii453
Open AccessSP228ELECTRONIC CLINICAL DECISION SUPPORT FOR THE EARLY RECOGNITION AND MANAGEMENT OF ACUTE KIDNEY INJURY: QUANTITATIVE EVALUATION OF OUTCOMES
Introduction and Aims: Electronic clinical decision support (eCDS) systems have been promoted to help address deficiencies in AKI care and have been widely adopted despite limited published evidence. However, eCDS implementation in other settings has been hampered by alert fatigue, end-user disengagement and unintended clinical consequences. These impediments to integration may hinder progress against the clinical outcomes which these tools were intended to target. With clinical efficacy, therefore, still uncertain, we undertook a single-centre, quantitative evaluation of outcomes after implementation of an AKI eCDS system within our organisation.
- 7 October 2014
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 52 (2) , 193-205
Pathophysiology of ischaemic acute kidney injury
Acute kidney injury is common, dangerous and costly, affecting around one in five patients emergency admissions to hospital. Although survival decreases as disease worsens, it is now apparent that even modest degrees of dysfunction are not only associated with higher mortality but are an independent risk factor for death. This review focuses on the pathophysiology of acute kidney injury secondary to ischaemia – its commonest aetiology. The haemodynamic disturbances, endothelial injury, epithelial cell injury and immunological mechanisms underpinning its initiation and extension will be discussed along with the considerable and complex interplay between these factors that lead to an intense, pro-inflammatory state. Mechanisms of tubular recovery will be discussed but also the pathophysiology of abnormal repair with its direct consequences for long-term renal function. Finally, the concept of ‘organ cross-talk’ will be introduced as a potential explanation for the higher mortality observed with acute kidney injury that might be deemed modest in conventional biochemical terms.
- 7 October 2014
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 52 (2) , 193-205
Pathophysiology of ischaemic acute kidney injury
Acute kidney injury is common, dangerous and costly, affecting around one in five patients emergency admissions to hospital. Although survival decreases as disease worsens, it is now apparent that even modest degrees of dysfunction are not only associated with higher mortality but are an independent risk factor for death. This review focuses on the pathophysiology of acute kidney injury secondary to ischaemia – its commonest aetiology. The haemodynamic disturbances, endothelial injury, epithelial cell injury and immunological mechanisms underpinning its initiation and extension will be discussed along with the considerable and complex interplay between these factors that lead to an intense, pro-inflammatory state. Mechanisms of tubular recovery will be discussed but also the pathophysiology of abnormal repair with its direct consequences for long-term renal function. Finally, the concept of ‘organ cross-talk’ will be introduced as a potential explanation for the higher mortality observed with acute kidney injury that might be deemed modest in conventional biochemical terms.